Acceso usuarios
Diane S. Aschenbrenner
* Canagliflozin (Invokana) is the first drug in a new class approved for the treatment of type 2 diabetes.
* It promotes the renal excretion of glucose and, consequently, diuresis; as a result, patients can develop hypovolemia and hypotension.
* Canagliflozin should be avoided in patients with serious renal insufficiency.
